chemistry

Lazertinib

Lazertinib is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Lazertinib rather than just read about it. In short: Lazertinib, sold under the brand names Lazcluze and Leclaza among others, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is a kinase inhibitor of epidermal growth factor receptor.

Key takeaways

Lazertinib belongs to chemistry; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Lazertinib to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Lazertinib from memory before moving on to harder problems.

Reference excerpt

Lazertinib, sold under the brand names Lazcluze and Leclaza among others, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is a kinase inhibitor of epidermal growth factor receptor. The most common adverse reactions include rash, nail toxicity, infusion-related reactions (amivantamab), musculoskeletal pain, edema, stomatitis, venous thromboembolism, paresthesia, fatigue, diarrhea, constipation, COVID-19 infection, hemorrhage, dry skin, decreased appetite, pruritus, nausea, and ocular toxicity. Lazertinib was approved for medical use in South Korea in January 2021, in the United States in August 2024, and in the European Union in January 2025.

Medical uses Lazertinib is indicated, in combination with amivantamab, for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations.

History Efficacy was evaluated in MARIPOSA (NCT04487080), a randomized, active-controlled, multi-center trial of 1074 participants with exon 19 deletion or exon 21 L858R substitution mutation-positive locally advanced or metastatic non-small cell lung cancer and no prior systemic therapy for advanced disease. Participants were randomized (2:2:1) to receive lazertinib in combination with amivantamab, osimertinib monotherapy, or lazertinib monotherapy (an unapproved regimen for non-small cell lung cancer) until disease progression or unacceptable toxicity. The US Food and Drug Administration (FDA) approved lazertinib in combination with amivantamab based on evidence from one clinical trial (MARIPOSA, NCT04487080) using data from 858 adult participants with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations. The trial was conducted at 204 sites in 26 countries including China, South Korea, Brazil, Japan, Malaysia, Spain, Taiwan, Russian Federation, Turkey, Thailand, Mexico, France, Italy, Ukraine, Argentina, Poland, the United States, India, Australia, Portugal, Israel, the United Kingdom, Germany, Belgium, Hungary, and Netherlands. Of the 858 participants, 12 were enrolled at sites in the United States. Among the 858 participants, all were evaluated for efficacy and 849 were evaluated for safety.

Society and culture

Legal status Lazertinib was approved for medical use in the United States in August 2024. In November 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Lazcluze, intended in combination with amivantamab, for the treatment of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. The applicant for this medicinal product is Janssen-Cilag International NV. Lazertinib was authorized for medical use in the European Union in January 2025.

Names Lazertinib is the international nonproprietary name. Lazertinib is sold under the brand name Lazcluze and in South Korea as Leclaza.

References

External links Clinical trial number NCT04487080 for "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)" at ClinicalTrials.gov

Illustrations

Worked examples

Example 1 — a first encounter with Lazertinib

Start with the simplest possible case. Write down what Lazertinib claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Lazertinib before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Lazertinib ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Lazertinib

In research: Lazertinib appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Lazertinib in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Lazertinib is common in secondary-school and first-year university syllabi. It links to neighbouring topics 4-Morpholinyl compounds, Anilides, Dimethylamino compounds, so understanding it makes those chapters shorter.
In everyday life: Look for Lazertinib outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Lazertinib” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Lazertinib in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Lazertinib means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Lazertinib out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Lazertinib in simple terms?

Why does Lazertinib matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Lazertinib?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Lazertinib.